The Chernin Group-backed series D round valued the medical test provider at $1.3bn while pushing its total funding past $250m.

US-based medical test access provider Everlywell received $175m in series D financing yesterday from investors including over-the-top media company The Chernin Group, at a valuation reported by Forbes to be $1.3bn.

Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures, Portfolia, Goodwater Capital, Highland Capital Partners and Next Coast Ventures also took part in the round along with funds and accounts managed by BlackRock.

Everlywell has built a digital platform that allows users to get access to federally approved testing kits…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn